Costs of laboratory
procedures for NSCLC patients are substantial. Relatively simple blood tests contribute
significantly to these costs due to high test volumes. Main cost driver however
is molecular testing by the pathologist, for the use of targeted therapies. In pharmacoeconomic
evaluations, taking laboratory costs into account significantly impacts
results, especially when testing practices differ between treatment alternatives